Hoth Therapeutics, Inc. (HOTH): Price and Financial Metrics
HOTH Price/Volume Stats
| Current price | $1.17 | 52-week high | $4.30 |
| Prev. close | $1.19 | 52-week low | $0.99 |
| Day low | $1.15 | Volume | 16,648 |
| Day high | $1.21 | Avg. volume | 397,216 |
| 50-day MA | $1.31 | Dividend yield | N/A |
| 200-day MA | $1.59 | Market Cap | 5.72M |
HOTH Stock Price Chart Interactive Chart >
Hoth Therapeutics, Inc. (HOTH) Company Bio
Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.
Latest HOTH News From Around the Web
Below are the latest news stories about HOTH THERAPEUTICS INC that investors may wish to consider to help them evaluate HOTH as an investment opportunity.
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of MiamiHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has received approval from the University of Miami to enroll patients for its first in human clinical trial of HT-001. |
Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling StudiesHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has completed the manufacturing of its drug substance HT-KIT using good laboratory practice (GLP). HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting and already has Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). Hoth also recently completed its Pre-IND meeting with FDA in November. |
Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KITHoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today the successful completion of a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for its HT-KIT therapeutic. The Pre-IND meeting was completed through written responses provided by the FDA Nonmalignant Hematology Division of Regulatory Operations for Cardiology, Hematology, Endocrinology, and Nephrology. |
Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to present at the NobleCon 19th Annual Emerging Growth Investor Conference in Boca Raton, FL. |
Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug DiscoveryHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced, its initiative to utilize Artificial Intelligence to both screen its current pipeline as well as utilize AI for licensing opportunities in acquiring or partnering novel therapeutics for rare diseases. |
HOTH Price Returns
| 1-mo | -23.03% |
| 3-mo | -10.00% |
| 6-mo | 0.86% |
| 1-year | -38.42% |
| 3-year | -96.94% |
| 5-year | -99.10% |
| YTD | -18.75% |
| 2023 | -81.54% |
| 2022 | -52.72% |
| 2021 | -72.16% |
| 2020 | -61.71% |
| 2019 | N/A |
Loading social stream, please wait...